Maravai LifeSciences
MRVI
228 hedge funds and large institutions have $6.27B invested in Maravai LifeSciences in 2021 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 91 increasing their positions, 55 reducing their positions, and 32 closing their positions.
103% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 32
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
65% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 55
31% more capital invested
Capital invested by funds: $4.77B → $6.27B (+$1.5B)
16% more funds holding
Funds holding: 196 → 228 (+32)
11.7% more ownership
Funds ownership: 100% → 111.7% (+12%)
26% less call options, than puts
Call options by funds: $13.8M | Put options by funds: $18.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$255M |
| 2 |
Select Equity Group
New York
|
+$209M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$85.8M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$69M |
| 5 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
+$57.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GL
GTCR LLC
Chicago,
Illinois
|
-$143M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$124M |
| 3 |
Lazard Asset Management
New York
|
-$66.7M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$50.8M |
| 5 |
HM
HealthCor Management
New York
|
-$49.1M |
MRVI Hedge Fund Activity: Q3 2021 in Review
228 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q3 2021, worth a combined $6.27B — up 31% from $4.77B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new MRVI positions and 32 closed out — a net gain of 33 holders — while 91 added to existing stakes and 55 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $255M. The largest seller was GTCR LLC, cutting an estimated $143M.
- 228 institutional investors held Maravai LifeSciences (MRVI) as of Q3 2021, up from 196 in Q2 2021.
- Funds reported $6.27B of Maravai LifeSciences stock for Q3 2021, up 31% quarter-over-quarter.
- 65 funds opened new Maravai LifeSciences positions in Q3 2021 and 32 closed out, a net change of +33 holders.
- The largest Maravai LifeSciences buyer in Q3 2021 was Fidelity Investments, an estimated $255M added.
- The largest Maravai LifeSciences seller in Q3 2021 was GTCR LLC, an estimated $143M sold.
Based on aggregated 13F filings for Q3 2021.